Abstract
A randomized multicentre study was conducted to evaluate the effect of anti-CMV hyperimmune globulin in the prophylaxis of CMV infections in CMV seronegative allogeneic BMT patients who received a transplant from a seropositive donor or who had received blood products unscreened for CMV during the treatment before BMT. Twenty-eight patients were included in the study. Thirteen were randomized to receive and 15 not to receive intravenous CMV hyperimmune globulin. A dose of 0.4 g/kg of immunoglobulin was given on day −8 and 0.2 g/kg on days −1, +7, +14, +21, +28, +35, +42, +56 and +70 in relation to the day of transplantation. Among the 15 patients not given immunoglobulin CMV was isolated in three, and two of them developed clinical CMV disease. In addition, one more patient developed CMV antibodies without virus isolation. In five of the 13 patients given immunoglobulin the virus could be isolated, and four of them developed CMV disease. One additional patient showed seroconversion but no other findings of CMV infection. The incidence of acute and chronic GVHD was similar in the two arms. There was no significant difference in survival. In conclusion, the present results do not indicate a beneficial effect of CMV hyperimmune globulin infusions in the prophylaxis of CMV infection or disease in seronegative allogeneic bone marrow transplant recipients from a seropositive donor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ruutu, T., Ljungman, P., Brinch, L. et al. No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. Bone Marrow Transplant 19, 233–236 (1997). https://doi.org/10.1038/sj.bmt.1700649
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700649
Keywords
This article is cited by
-
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy
Current Hematologic Malignancy Reports (2020)
-
Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016
Annals of Hematology (2016)
-
The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients
Cellular and Molecular Life Sciences (2015)
-
Cytomegalovirus infection/disease after hematopoietic stem cell transplantation
International Journal of Hematology (2010)
-
Management of CMV infections: recommendations from the infectious diseases working party of the EBMT
Bone Marrow Transplantation (2004)